VIRIDIAN THERAPEUTICS, INC.\DE (VRDN)
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
📈 **POSITIVE** • High confidence analysis (82%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business